http://www.remediesarthritis.com All About Arthritis And Arthritis Treatment Thu, 11 Mar 2010 18:21:00 +0000 http://backend.userland.com/rss092 en Swiss drugmaker Roche Holding AG and U.S. biotechnology company Biogen Idec are suspending rheumatoid arthritis and lupus treatment ocrelizumab after it caused deaths, casting doubt over the drug's future. ... See more here: Roche, Biogen suspend arthritis drug after deaths (Reuters via Yahoo! News) http://www.remediesarthritis.com/roche-biogen-suspend-arthritis-drug-after-deaths-reuters-via-yahoo-news.html http://www.youtube.com/v/5iUYxYvViLI?f=videos&app=youtube_gdata http://www.remediesarthritis.com/medical-seminar-arthritis-pain-treatment-part-3.html Roche and Biogen Idec announced their decision to suspend Ocrelizumab treatment of patients in the Rheumatoid Arthritis (RA) programme. ... Read more: Roche, Biogen Idec to suspend Ocrelizumab treatment of patients in RA programme (PharmaBiz) http://www.remediesarthritis.com/roche-biogen-idec-to-suspend-ocrelizumab-treatment-of-patients-in-ra-programme-pharmabiz.html Results from a study conducted by Majestic Research suggest that Bristol Myers Squibb's Orencia, Johnson & Johnson's Remicade, and Amgen's/Wyeth's Enbrel will forfeit share of the rheumatoid arthritis market to Roche's newly launched Actemra. Early switching data from Majestic’s proprietary panel of rheumatologists indicates that Orencia may be the biggest ... http://www.remediesarthritis.com/study-finds-sizeable-position-for-actemra-in-rheumatoid-arthritis-treatment-paradigm-news-medical-net.html Roche and Biogen Idec announced recently their decision to suspend Ocrelizumab treatment of patients in the Rheumatoid Arthritis (RA) programme. ... Read more from the original source: Roche And Biogen Idec Decide To Suspend Ocrelizumab Treatment - Rheumatoid Arthritis Development Programme On Hold (PharmaceuticalOnline) http://www.remediesarthritis.com/roche-and-biogen-idec-decide-to-suspend-ocrelizumab-treatment-rheumatoid-arthritis-development-programme-on-hold-pharmaceuticalonline.html Swiss drugmaker Roche Holding AG and U.S. biotechnology company Biogen Idec are suspending experimental rheumatoid arthritis and lupus treatment ocrelizumab after deaths following its use, casting doubt over its future. ... Follow this link: Roche, Biogen suspends arthritis drug after deaths (Reuters via Yahoo! News) http://www.remediesarthritis.com/roche-biogen-suspends-arthritis-drug-after-deaths-reuters-via-yahoo-news.html Ipsen (Paris:IPN) (Euronext: FR0010259150; IPN), a global biotechnology specialty care group and Menarini, the first Italian pharmaceutical Group in the world with a significant pan-European presence, announced the launch of ADENURIC® (febuxostat) in France where they will co-promote the drug. Other launches by Menarini are planned shortly, notably in United ... http://www.remediesarthritis.com/launch-by-menarini-and-ipsen-of-adenuricr-febuxostat-in-france-for-the-treatment-of-chronic-hyperuricemia-in-gout-medical-news-today.html Peptimmune, Inc. a privately held biotechnology company, announced today the grant of US Patent Number 7,655,221 (the '221 patent) which protects the target product profile for its PI-2301 peptide copolymer for the treatment of multiple sclerosis, and other autoimmune diseases. ... Read more from the original source: Peptimmune granted US patent for ... http://www.remediesarthritis.com/peptimmune-granted-us-patent-for-pi-2301-peptide-copolymer-in-treatment-of-multiple-sclerosis-news-medical-net.html Michelle and Tim Banic understand when people think that only elderly people get arthritis. ... View post: Arthritis affects children, not just seniors (Kitchener - Waterloo Record) http://www.remediesarthritis.com/arthritis-affects-children-not-just-seniors-kitchener-waterloo-record.html NICE's independent appraisal committee has asked Roche, the manufacturer of tocilizumab (RoActemra), a new treatment for moderate to severe active rheumatoid arthritis, for further additional information on its product. The committee is minded not to recommend the use of the drug but the additional information it has asked for today ... http://www.remediesarthritis.com/nice-asks-for-more-data-on-new-drug-for-rheumatoid-arthritis-medical-news-today.html